.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Management and Treatment of Chronic Myeloid Leukemia

EP. 1: Introduction: Role of Genetic Testing in CML

January 14th 2015

EP. 2: Optimal Timing for Follow-up Mutation Testing in CML

January 14th 2015

EP. 3: Importance of Monitoring Patients With CML

January 14th 2015

EP. 4: Treatment Selection for Newly Diagnosed Patients With CML

January 14th 2015

EP. 5: First-Line Dasatinib in Chronic Myeloid Leukemia

January 14th 2015

EP. 6: Promises and Challenges of Ponatinib in CML

January 14th 2015

EP. 7: Dasatinib in the Second-Line CML Setting

January 14th 2015

EP. 8: First- and Second-Line Nilotinib in CML

January 14th 2015

EP. 9: Utilizing Second-Line Bosutinib in Ph+ CML

January 14th 2015

EP. 10: Ponatinib Effective in Resistant CML

January 14th 2015

EP. 11: Utilizing Omacetaxine in Chronic Myeloid Leukemia

January 14th 2015

EP. 12: Addressing Fluctuating BCR-ABL Levels in CML

January 14th 2015

EP. 13: Feasibility of TKI Discontinuation in CML

January 14th 2015

EP. 14: Final Comments From Panelists on Managing CML

January 14th 2015